Physician profile
Brian Gonzales
NPI 1720150915
$3,704.86
in general payments reported to CMS, 2019-2025
25 companies · $741 in 2025
The $741 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $156 · 2021: $139 · 2022: $472 · 2023: $895 · 2024: $1,144 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,779.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $546.12 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $535.22 | 2022-2025 | Cequa |
| Alcon Vision LLC | $351.66 | 2020-2025 | Precision7, Total30, Clareon |
| Tarsus Pharmaceuticals, INC. | $310.57 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $271.83 | 2021-2023 | |
| Abbvie INC. | $217.19 | 2023-2025 | |
| Rxsight INC | $211.03 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Oyster Point Pharma, INC. | $208.23 | 2022-2024 | Tyrvaya |
| Amgen INC. | $190.12 | 2024-2025 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $189.53 | 2019-2024 | Acuvue |
| Dompe US, INC. | $138.91 | 2020-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $93.69 | 2019-2021 | |
| Harrow Eye, LLC | $80.48 | 2024-2025 | Vevye |
| Thea Pharma INC. | $63.11 | 2023-2025 | Iyuzeh |
| Kala Pharmaceuticals, INC. | $60.20 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $40.77 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $29.27 | 2021 | |
| Coopervision INC. | $26.26 | 2025 | Myday Contact Lens |
| Horizon Therapeutics Plc | $26.08 | 2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $24.75 | 2023 | |
| Ocular Therapeutix, INC. | $19.82 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $19.48 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Glaukos Corporation | $18.36 | 2022 | |
| Eyevance Pharmaceuticals LLC | $12.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Gonzales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.